Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA harmonization task force report

Executive Summary

Has been completed and will be available within two weeks from the National Technical Information Services (NTIS). In Dec. 9 "Talk Paper," FDA said the report "makes recommendations for future agency activities and calls for continuing discussions" in the GATT and NAFTA talks, with the European community and "in other forums," to "encourage international cooperation." FDA says the report also "addresses the need for adequate resources to carry out international programs and cites increased costs, such as those required for conducting foreign inspections, as a driving force" for efforts to harmonize manufacturing standards and enforcement. FDA points out that it has Memoranda of Understanding on GMP inspections with Canada, Sweden and Switzerland and the agency "is exploring the possibility of agreements with Japan, Australia, the EC and others".

Latest Headlines
See All
UsernamePublicRestriction

Register

PS021895

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel